FDA Approves Regeneron's Pasatru, First Drug to Reduce New Bone Lesions in FOP
REGN sits 55% above its 52-week low of $541.
Summary
Regeneron won FDA approval for Pasatru (garetosmab-grts), the first and only treatment shown to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). The approval is based on the Phase 3 OPTIMA trial, where Pasatru cut new HO lesions by 90% and 94% at the two doses versus placebo, and reduced clinician-assessed flare-ups by 88% and 15%. FOP is an ultra-rare disease affecting roughly 900 people worldwide, but this approval validates Regeneron's Activin A discovery and adds a new commercial product to its rare disease portfolio. The company plans a pediatric trial (OPTIMA 2) later this year and has regulatory submissions under review in the EU and planned in Japan. This is a meaningful pipeline-to-market event for a large-cap biotech, though the ultra-rare patient population limits near-term revenue impact.
At the time of this announcement, REGN was trading at $840.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $86.5B. The 52-week trading range was $541.00 to $843.26. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.